Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ER<sup>T2</sup> System.

导出 OA

翻译打印收藏纠错

作者： Leonid A,Ilchuk ^[1] ; Nina I,Stavskaya ^[2] ; Ekaterina A,Varlamova ^[1] ; Alvina I,Khamidullina ^[3] ; Victor V,Tatarskiy ^[2] ; Vladislav A,Mogila ^[2] ; Ksenia B,Kolbutova ^[2] ; Sergey A,Bogdan ^[4] ; Alexey M,Sheremetov ^[4] ; Alexandr N,Baulin ^[4] ; Irina A,Filatova ^[4] ; Yulia Yu,Silaeva ^[4] ; Maxim A,Filatov ^[2] ; Alexandra V,Bruter ^[1]

作者单位： Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia. ^[1] Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334 Moscow, Russia. ^[2] Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation, Kashirskoe Sh., 24, 115478 Moscow, Russia. ^[3] Head Center of Hygiene and Epidemiology of Federal Medical Biological Agency of Russia, 1st Pekhotniy Pereulok, 6, 123182 Moscow, Russia. ^[4]

关键词 Cre-ERT2 Cre-LoxP conditional knockout cyclin-dependent kinases 8/19 genetically engineered mice genome-edited mice tamoxifen

主题词动物(Animals);女(雌)性(Female);小鼠(Mice);多西环素(Doxycycline);整合酶类(Integrases);小鼠, 转基因(Mice, Transgenic);他莫昔芬(Tamoxifen)

DOI 10.3390/ijms232214077

PMID 36430553

发布时间 2022-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交